Please login to the form below

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and

Latest news

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia
Opdivo drives gain in BMS sales, but business revamp coming

Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
Shire gives up on Momenta-partnered Humira biosimilar

It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate

The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) which brought in sales of
NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira. NICE has recommended four drugs in draft guidance for the treatment of juvenile idiopathic arthritis (JIA). ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab),

More from news
Approximately 8 fully matching, plus 28 partially matching documents found.

Latest Intelligence

Deal Watch January 2016

255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept) . 245. Athersys/ Healios. Licence. Development and commercialisation
Biosimilars - the same, but different?

Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS’ Brian Daniels to retire

Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director- Flexible Working: Negotiable

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Events Executive: DOE

Account Director – UK Office: Excellent salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...